190 related articles for article (PubMed ID: 7520953)
1. [The usefulness of early whole body bone scintigraphy in the detection of bone metastasis from prostatic cancer].
Otsuka N; Fukunaga M; Furukawa Y; Tanaka H
Kaku Igaku; 1994 Jun; 31(6):541-50. PubMed ID: 7520953
[TBL] [Abstract][Full Text] [Related]
2. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
Hetherington JW; Siddall JK; Cooper EH
Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
[TBL] [Abstract][Full Text] [Related]
3. [Clear skeletal visualization on whole body 201Tl-chloride scintigraphy: a case of prostatic cancer with diffuse bone metastases].
Tsubuku M; Hayashi S; Itoh K; Kaneko I; Shimada M; Akasaka Y; Kusama K; Kogure T
Kaku Igaku; 1995 Nov; 32(11):1249-53. PubMed ID: 8558793
[TBL] [Abstract][Full Text] [Related]
4. [Bone scintigraphy in bone metastases due to prostatic cancer].
Hidaka H; Ishino Y; Nakayama C; Nakata H; Okamura T
J UOEH; 1987 Dec; 9(4):369-77. PubMed ID: 3438611
[TBL] [Abstract][Full Text] [Related]
5. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
[TBL] [Abstract][Full Text] [Related]
6. [Detection of bone metastasis of prostate cancer - comparison of whole-body MRI and bone scintigraphy].
Ketelsen D; Röthke M; Aschoff P; Merseburger AS; Lichy MP; Reimold M; Claussen CD; Schlemmer HP
Rofo; 2008 Aug; 180(8):746-52. PubMed ID: 18512192
[TBL] [Abstract][Full Text] [Related]
7. [The early scintigraphic diagnosis of bone metastases in prostatic carcinoma].
Petrov T; Tsvetkov M; Mladenov D; Kumanov Kh
Khirurgiia (Sofiia); 1991; 44(5):28-9. PubMed ID: 1844461
[TBL] [Abstract][Full Text] [Related]
8. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
9. [Relation between serum PAP (prostate acid phosphatase) and bone scintigraphy in prostatic cancer].
Aizawa T; Itoh T; Tsujino S; Namiki K; Miki M
Kaku Igaku; 1992 Nov; 29(11):1277-83. PubMed ID: 1484418
[TBL] [Abstract][Full Text] [Related]
10. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
Wakabayashi H; Nakajima K; Mizokami A; Namiki M; Inaki A; Taki J; Kinuya S
Ann Nucl Med; 2013 Nov; 27(9):802-7. PubMed ID: 23828554
[TBL] [Abstract][Full Text] [Related]
11. Quantitative bone scintigraphy and 24-hour whole-body counting of 99mTc-methylene diphosphonate in patients with prostatic carcinoma.
Sundkvist GM; Ahlgren L; Lilja B; Mattsson S
Nuklearmedizin; 1992 Oct; 31(5):178-81. PubMed ID: 1465355
[TBL] [Abstract][Full Text] [Related]
12. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
[TBL] [Abstract][Full Text] [Related]
13. The usefulness of bone-marrow scintigraphy in the detection of bone metastasis from prostatic cancer.
Otsuka N; Fukunaga M; Sone T; Yoneda M; Saito N; Tanaka H; Tomomitsu T; Yanagimoto S; Muranaka A; Morita R
Eur J Nucl Med; 1985; 11(8):319-22. PubMed ID: 4076240
[TBL] [Abstract][Full Text] [Related]
14. [Bone scintigraphy for diagnosis of bone metastasis in patients with prostatic cancer].
Nakashima J
Nihon Rinsho; 2002 Dec; 60 Suppl 11():135-9. PubMed ID: 12599559
[No Abstract] [Full Text] [Related]
15. Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit.
Kida T; Higuchi Y
Oncology; 1983; 40(5):346-50. PubMed ID: 6621997
[TBL] [Abstract][Full Text] [Related]
16. Quantitative bone scintigraphy: usefulness in the survey of patients treated for bone metastasis of prostatic cancer.
Grob JC; Lallot C; Methlin G; Bollack C
Eur Urol; 1988; 15(3-4):193-5. PubMed ID: 3145888
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow scintigraphy in the diagnosis of bone metastasis in prostate cancer.
Fuse H; Nagakawa O; Seto H; Katayama T
Int Urol Nephrol; 1994; 26(1):53-61. PubMed ID: 8026923
[TBL] [Abstract][Full Text] [Related]
18. Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI) study.
Nakajima K; Kaneko G; Takahashi S; Matsuyama H; Shiina H; Ichikawa T; Horikoshi H; Hashine K; Sugiyama Y; Miyao T; Kamiyama M; Harada K; Ito A; Mizokami A;
Int J Urol; 2018 May; 25(5):492-499. PubMed ID: 29633398
[TBL] [Abstract][Full Text] [Related]
19. Scintigraphic changes in bone metastasis from prostate cancer after hormonal therapy--comparison with tumor markers and bone X-ray.
Koizumi K; Uchiyama G; Komatsu H
Ann Nucl Med; 1994 Nov; 8(4):225-30. PubMed ID: 7535550
[TBL] [Abstract][Full Text] [Related]
20. [A comparaison between the total PSA, the Gleason score and the bone scintiscan results for different age groups].
Rusu D; Rusu V; Stefănescu C; Rusu M; Răileanu I; Stătescu AM
Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):476-83. PubMed ID: 20700990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
